UNIVERSITY of York

This is a repository copy of *miR-132* suppresses transcription of ribosomal proteins to promote protective Th1 immunity.

White Rose Research Online URL for this paper: <u>https://eprints.whiterose.ac.uk/143286/</u>

Version: Accepted Version

Article:

Hewitson, James Philip orcid.org/0000-0002-3265-6763, Shah, Kunal M, Brown, Najmeeyah et al. (6 more authors) (2019) miR-132 suppresses transcription of ribosomal proteins to promote protective Th1 immunity. EMBO Reports. e46620. ISSN 1469-221X

https://doi.org/10.15252/embr.201846620

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk https://eprints.whiterose.ac.uk/

1	miR-132 suppresses transcription of ribosomal proteins to promote protective
2	Th1 immunity
3	
4	James P. Hewitson ¹ , Kunal M. Shah ² , Najmeeyah Brown ¹ , Paul Grevitt ² , Sofia
5	Hain ¹ , Katherine Newling ³ , Tyson V. Sharp ² , Paul M. Kaye ¹ , and Dimitris Lagos ^{1*}
6	
7	1. Centre for Immunology and Infection, Hull York Medical School and Department of
8	Biology, University of York, Wentworth Way, York, YO10 5DD, UK.
9	2. Centre of Molecular Oncology, Barts Cancer Institute, John Vane Science Centre,
10	Charterhouse Square, Queen Mary University London, London, EC1M 6BQ, UK.
11	3. Genomics and Bioinformatics Laboratory, Bioscience Technology Facility,
12	Department of Biology, University of York, Wentworth Way, York, YO10 5DD, UK.
13	* Corresponding author: dimitris.lagos@york.ac.uk, ORCID: 0000-0003-0637-281X.
14	
15	Running title: The miR-132/212 cluster promotes protective immunity
16	Keywords: miR-132, microRNA, ribosomal proteins, leishmania, Th cells
17	
18	Short summary
19	The miR-132/212 cluster suppresses generation of IL-10-expressing Th1 cells
20	during chronic infection. This is associated with miR-132/212-mediated
21	suppression of ribosomal protein transcription in Th1 cells through silencing
22	BTAF1 and p300.
23	
24	Highlights
25	- The transcriptomic hallmark of miR-132/212 deficiency in splenic CD4 $^{\scriptscriptstyle \rm T}$ cells
26	during chronic infection with Leishmania donovani is an up-regulation of several
27	ribosomal protein genes.

28 - The miR-132/212 cluster controls ribosomal protein expression through directly

29 targeting two transcriptional co-activators, BTAF1 and p300.

30 - Leishmania donovani-infected miR-132/212^{-/-} mice display increased IL-10 and
 31 reduced IFNγ protein expression in Th1 cells, reduced hepatosplenomegaly, and
 32 increased parasite burdens.

33

34 ABSTRACT

35 Determining the mechanisms that distinguish protective immunity from 36 pathological chronic inflammation remains a fundamental challenge. miR-132 has 37 been shown to play largely immunoregulatory roles in immunity, however its role in CD4⁺ T cell function is poorly understood. Here, we show that CD4⁺ T cells 38 39 express high levels of miR-132 and that T cell activation leads to miR-132 up-40 regulation. The transcriptomic hallmark of splenic CD4⁺ T cells lacking the miR-41 132/212 cluster during chronic infection is an increase in mRNAs levels of 42 ribosomal protein (RP) genes. BTAF1, a co-factor of B-TFIID and novel miR-43 132/212-3p target, and p300 contribute towards miR-132/212-mediated regulation of RP transcription. Following infection with Leishmania donovani miR-132^{-/-} CD4⁺ 44 45 T cells display enhanced expression of IL-10 and decreased IFN γ . This is associated with reduced hepatosplenomegaly and enhanced pathogen load. The 46 47 enhanced IL-10 expression in *miR-132^{-/-}* Th1 cells is recapitulated *in vitro* following treatment with phenylephrine, a drug reported to promote ribosome 48 49 synthesis. Our results uncover that miR-132/212-mediated regulation of RP 50 expression is critical for optimal CD4⁺ T cell activation and protective immunity 51 against pathogens.

52

53 INTRODUCTION

54 MicroRNAs (miRNAs) are endogenous small silencing RNAs with fundamental roles in 55 the immune system [1]. In this context, miR-132-3p (miR-132) is derived from the miR-56 212/132 cluster and has emerged as key regulator of immune cell development and 57 function [1, 2]. During innate immune activation, miR-132 is induced upon and plays a 58 crucial role in the transcriptional response to pathogenic challenge [3-6]. We have 59 previously shown that miR-132 is induced in a dose-dependent manner upon viral 60 infection and suppresses the innate antiviral immune response by down-regulating 61 expression of p300 (official symbol EP300), a necessary co-activator for several key 62 transcription factors [3]. Furthermore, miR-132 has been shown to be critical for normal 63 haematopoiesis and B cell development and function through suppression of FOXO3 64 and SOX4, respectively [7, 8], whereas the miR-212/132 cluster has also been 65 implicated in Th17 responses [9]. miR-132 is also up-regulated in a model of 66 inflammation-induced cellular transformation [10], plays a key role inflammation during 67 wound healing [11], is induced in vivo following infection by Toxoplasma gondii [12], and 68 regulates macrophage activation following Mycobacterium tuberculosis infection [13]. 69 Although the above studies have provided strong support for the role of miR-132 in the 70 immune system, they have predominantly focused on acute inflammation or infection 71 models whereas the role of miR-132 in models of pathogen-induced chronic 72 inflammation remains poorly explored. For example, we have limited knowledge on 73 whether miR-132 is dispensable for T cell-mediated immunity.

74

Here we show that miR-132 is induced upon activation of CD4⁺ T cells *in vitro* and *in vivo* during infection of mice with *Leishmania donovani* (*L. donovani*). Using fully *miR-212/132*-deficient mice [14] (hereafter referred to as *miR-132^{-/-}* mice), we show that the transcriptomic hallmark of miR-132 deficiency in CD4⁺ T cells isolated from chronically infected spleens is an increase in mRNAs levels of ribosomal protein (RP) genes. Similarly, miR-132 controls RP gene mRNA levels during *in vitro* activation of CD4⁺ T cells. Enhanced ribosome biosynthesis during *in vitro* CD4⁺ T cell activation is thought

82 to be necessary for accommodating the needs for cytokine production in activated cells 83 [15]. However, the in vivo relevance of this phenomenon and the molecular drivers underpinning it remain largely unexplored. Notably, miR-132 over-expression 84 85 suppresses RP gene expression and protein synthesis rates in mouse embryonic 86 fibroblasts (MEFs). Regulation of RP gene expression is mediated by miR-132-mediated silencing of proteins involved in transcription including p300 and BTAF1, which we 87 identified here as a novel miR-132 target. In vivo, miR-132^{-/-} CD4⁺ T cells from 88 89 chronically infected mice express higher levels of IL-10 and lower levels of IFNy when 90 compared to WT cells. This functional impairment correlates with reduced immunopathology and increased pathogen burdens in L. donovani-infected miR-132-/-91 mice. In vitro, activated miR-132^{-/-} CD4⁺ T cells treated with the hypertrophic factor 92 93 phenylephrine (PE) also demonstrate enhanced IL-10 expression. Overall, the above 94 demonstrate that miR-132 is a necessary and sufficient regulator of RP gene expression 95 through targeting core transcriptional regulators and that this mechanism contributes 96 towards optimal CD4⁺ T cell activation and protective immunity.

97

98 RESULTS AND DISCUSSION

99 miR-132 is up-regulated during CD4⁺ T cell activation

100 We first determined whether miR-212/132 levels were regulated following stimulation of 101 naïve (CD62L⁺ CD44⁻) CD4 T cells with anti-CD3 and anti-CD28 antibodies, and found 102 strong miR-132-3p and -212-3p up-regulation that peaked at day 1 (18hrs) (Fig. 1A; ~20 103 and ~30 fold increase compared to unstimulated cells) and remained elevated for at 104 least 3 days. Expression of the miR-212/132 primary transcript is CREB-dependent [16], 105 and as expected [17], TCR stimulation induced strong CREB phosphorylation within 2-106 4 hours, and this was sustained for 3 days (Fig. EV1A). Whilst miR-146-5p showed little 107 change following T cell activation, miR-155-5p was strongly up-regulated for sustained periods, whereas miR-16-5p levels declined (Fig. 1A). miR-132-3p and miR-212-3p up-108

regulation appeared to be a common feature in activated CD4⁺ T cells, and occurred
regardless of T cell polarisation phenotype (Th0, Th1 and Th2; Fig. EV1B).

111 To investigate the role of miR-212/132 in the development of inflammation and protective immune responses in vivo, we studied its expression in naïve and infected 112 113 C57BL/6 WT mice with L. donovani amastigotes. This infection model allows the study of host-pathogen interactions [18], during which infection occurs in the liver, spleen, and 114 115 bone marrow. We sorted splenic lymphocytes and found that CD4⁺ T cells express higher miR-132-3p levels than CD8⁺ T cells or B cells (Fig. 1B). Furthermore, L. 116 donovani infection resulted in miR-132-3p up-regulation in CD4⁺ T cells. The extent of 117 this up-regulation was similar to that observed for miRNAs previously reported to be 118 119 involved in T cell responses such as 146-5p and 155-5p [19, 20]. Combining these 120 results with previous findings demonstrating miR-132 induction downstream of TLR [3-121 5] and the B cell receptor [7] establishes miR-132 induction as a hallmark of innate and 122 adaptive immune activation. Of note, miR-132 up-regulation has also been observed in 123 studies using human bulk CD4⁺ and CD8⁺ T cell populations where it was amongst the 124 most prominent up-regulated miRNAs [21].

125

miR-212/132-deficiency is associated with global up-regulation of ribosomal protein genes in CD4⁺ T cells from chronically infected spleens.

128 To gain a molecular understanding of the function of the miR-132/212 cluster in CD4⁺T 129 cells in vivo, we performed RNAseq analysis on biological replicates of sorted splenic CD4⁺ T cells from *L. donovani*-infected WT and *miR-132^{-/-}* mice. Of the more than 14,000 130 131 genes that were detectable in CD4⁺ T cells, similar numbers showed up- or downregulation by >50% in *miR-132^{-/-}* compared to WT cells (**Fig. 1C**; 10.3% up and 10.6%) 132 133 down). However, of the 1290 significantly differently expressed genes (9% of total), approximately 2/3 (850) were up-regulated in *miR-132^{-/-}* cells compared to WT and only 134 135 1/3 (440) down-regulated. Pathway analysis of genes significantly up-regulated in miR-132^{-/-} mice (p<0.05, >50% regulation) using the Gene Set Enrichment Analysis [22] and 136

STRING tools [23] revealed that a cluster of RP genes was significantly over-137 represented amongst genes upregulated in *miR-132^{-/-}* CD4⁺ T cells (Fig. 1D and 1E). 138 This up-regulation was evident for both small (RPS) and large (RPL) subunits protein 139 genes and even pseudogene transcripts (Fig. 1F). These results were further validated 140 141 by qPCR, showing an increase in all tested RP genes, reaching statistical significance for RPL27, RPS10 and RPL14-ps1 (Fig. 1G). To explore the significance of the 142 observed increase in RP gene expression in $miR-132^{-/-}$ CD4⁺ T cells, we analysed 143 published transcriptional profiles of in vitro generated Th1 and Th2 cells [24] and found 144 that CD4⁺ T cell activation results in a statistically significant shift towards global up-145 regulation of RP gene levels (Fig. 1H and Fig. EV1C). Taken together with previous 146 reports demonstrating that activation of ribosome biosynthesis is associated with 147 148 activation of CD8⁺ T cells [25] and production of cytokines by CD4⁺ T cells *in vitro* [15], our findings suggested that the observed RP gene up-regulation in $miR-132^{-/-}$ CD4⁺ T 149 150 cells was a signature of enhanced activation.

151

152 The B-TFIID cofactor BTAF1 is a direct miR-132 target in CD4⁺ T cells.

153 To identify direct targets of the miR-132/212 cluster in CD4⁺ T cells, we performed RNAseq analysis of naïve CD4⁺ T cells from WT and *miR-132^{-/-}* mice prior to and 154 155 following 1 day (18 hours) of in vitro TCR stimulation under Th1 conditions. We focussed 156 on Th1 responses as these predominate in L. donovani infection and these cells 157 displayed the highest levels of miR-132 expression (Fig. EV1B). Broadly similar 158 numbers of transcripts were detected in unstimulated and stimulated T cells (12336 and 159 11140, respectively), with 5.0% (day 0 = 615) and 3.9% (day 1 = 432) showing significant differences between WT and *miR-132^{-/-}* mice (Fig. 2A-B). A much larger number of 160 genes (44% WT, 54% miR-132---) were differentially expressed when we compared 161 162 naïve with activated T cells (Fig. EV2A-B). Of the genes that were significantly different between WT and *miR-132^{-/-}* mice (p<0.05; 50% difference), 46% were up-regulated in 163 $miR-132^{-/-}$ at day 0, and this increased to 68% at day 1. At day 1, we observed that the 164

165 majority of predicted miR-132/212-3p targets were up-regulated (i.e. 51/75 =68% 166 displayed a positive log2 fold change) in *miR-132^{-/-}* CD4⁺ T cells (**Fig. 2C-D**). Of note, a single predicted miR-132/212-3p target, BTAF1, was up-regulated in both unstimulated 167 and activated miR-132^{-/-} CD4⁺ T cells, as well as in CD4⁺ T cells from L. donovani-168 infected *miR-132^{-/-}* mice (Fig. 2C-E, and Fig. EV2C). Up-regulation of BTAF1 was 169 confirmed by qPCR (Fig. 2F). BTAF1 protein expression was elevated in miR-132^{-/-} 170 171 CD4⁺ T cells compared to WT cells, both before and after TCR stimulation (Fig. 2G). BTAF1 contains a single 7mer-m8 site for miR-132/212-3p within its 3'UTR that is 172 broadly conserved in mammals (Fig. EV2D). To assess whether BTAF1 was a direct 173 target of miR-132/212-3p, we transfected HeLa or 3T3 cells with luciferase reporter 174 constructs preceded by ~1.5kb of BTAF1 3'UTR (either WT or with miR-132/212-3p site 175 176 mutated) in the presence of miR-132-3p or miR-212-3p mimics. This revealed that in the 177 presence of miR-132-3p mimics, luciferase activity was significantly elevated following mutation of the miR-132/212 site in the 3'UTR (Fig. 2H, Fig. EV2E). A similar trend was 178 179 observed in miR-212-3p transfected cells although this did not reach statistical 180 significance. This demonstrated that miR-132 can directly interact with the predicted 181 miR-132-binding site in the BTAF1 3' UTR. We also searched for potential miR-132-5p and miR-212-5p targets that were altered in miR-132^{-/-} mice. Unlike miR-132-3p and 182 183 miR-212-3p, these two miRNA differ in their seed sequence and so are predicted to 184 have different mRNA targets (Fig. EV2F). Whilst several potential targets were 185 significantly dysregulated in miR-132^{-/-} CD4⁺ cells, there was little overlap between those 186 altered in unstimulated T cells, d1 activated T cells or those derived from d28 L. 187 donovani-infection (Fig. EV2G). Only a single target, BACH2 (predicted 7mer-A1 target 188 for both miR-212-5p and miR-132-5p), was up-regulated by >50% in all three T cell 189 datasets, but this was only significant for *in vitro* d1 stimulated T cells and was highly 190 variable in the other two conditions (Fig. EV2H).

Having observed an effect of miR-132 deletion on RP gene mRNA levels after chronic
CD4⁺ T cell activation *in vivo* (Fig. 1), we tested whether we can observe a similar effect

in our dataset from the early stages of *in vitro* CD4⁺ T cell activation. Following 24h of *in vitro* activation of naïve CD4⁺ T cells, we observed that 40% of RP genes showed upregulation (positive log₂ fold change or LFC) in *WT* mice. This proportion was significantly increased to 61% in *miR-132^{-/-}* mice (P = 0.011) (**Fig. EV2I**). Furthermore, the vast majority of RP genes (81%) demonstrated a higher LFC (indicating stronger upregulation or weaker downregulation) upon activation of *miR-132^{-/-}* CD4⁺ T cells compared to WT cells (**Fig. EV2J**).

200

p300 and BTAF1 contribute to miR-132-mediated suppression of ribosomal protein expression

203 miR-132 deficiency resulted in upregulation of several RP genes in CD4⁺ T cells from 204 chronically infected mice with L. donovani (Fig. 1). In addition, we found that miR-132-205 3p or miR-212-3p over-expression in mouse embryonic fibroblasts (MEFs) resulted in 206 widespread down-regulation of RP gene mRNA levels (Fig. 3A and EV3A). These 207 effects were confirmed at the protein level using Rpl27 and Rps10 as two representative 208 RPs (Fig. EV3B). This allowed us to further probe the mechanism employed by miR-209 132 to regulate ribosomal protein gene levels. The majority of RP transcripts upregulated in miR-132^{-/-} mice (Fig. 1D) lacked miR-132/212-3p sites (13/15 coding 210 211 transcripts), with the remaining 2/15 (RPL7L1 and RPL18) displaying non-conserved 212 sites. Predicted miR-132/212-3p targets are statistically significantly enriched in proteins 213 involved in transcription (Fig. EV3C). Therefore, we reasoned that the effect of miR-132 214 on RP gene expression was caused by miR-132-mediated suppression of transcriptional 215 regulators. For example, p300, a previously validated miR-132 target [3], is required for 216 the activity of Sp1, YY1 and CREB, all of which have known roles in transcription of RP 217 genes [26-28]. Of note, although miR-132 directly suppresses p300, its effects on p300 218 mRNA steady-state levels are minimal [3]. In parallel, BTAF1, a predominant miR-132 target in CD4⁺ T cells (Fig. 2) interacts with TATA-binding protein (TBP) to form B-TFIID, 219 220 causing redistribution of TBP to new genomic sites [29, 30]. Over-expression of miR-

221 132 in MEFs resulted in suppression of p300 and BTAF1 (Fig. 3B). Similarly, over-222 expression of miR-132-3p or miR-212-3p in the EL4 T cell line also resulted in suppression of BTAF1 and p300 (Fig. EV3D) suggesting that both miRNAs contribute 223 224 to regulation of BTAF1 and p300. Knockdown of p300 resulted in significant 225 downregulation of several miR-132-regulated RP transcript levels, including RPL27, 226 RPSA, RPS3A, RPS9, RPS10, and RPL14-ps1 (Fig. 3C), whereas levels of RPL18 227 showed a trend towards downregulation (P=0.06). In addition, knockdown of BTAF1 significantly reduced levels of RPL27 and RPL18, with RPL14-ps1 showing a trend 228 towards downregulation (P=0.052) (Fig. 3D). Critically, suppression of RP expression 229 by miR-132 was dependent on both p300 and BTAF1 (Fig. 3E). Although the majority 230 231 of miR-132-mediated effects on RP expression were abolished upon knockdown of 232 either p300 or BTAF1, we also identified RP mRNAs that were specifically dependent 233 on p300 (e.g. miR-132-mediated suppression of Rps9) or BTAF1 (e.g. miR-132-234 mediated suppression of RpI18; Fig. 3E). To validate the functional relevance of these 235 effects we tested protein synthesis rates in MEFs over-expressing miR-132-3p or miR-236 212-3p using a puromycin incorporation assay [31]. Over-expression of either of the two 237 miRNAs resulted in suppression of protein synthesis, consistent with their effect on RP 238 expression (Fig. 3F). These findings demonstrate that p300 and BTAF1, two miR-132 239 targets involved in transcription, contribute towards the widespread regulation of RP 240 genes observed in miR-132/212-deficient or over-expressing cells. Interestingly, Mot1, 241 the yeast homologue of BTAF1, promotes expression of ribosomal proteins in yeast [32], 242 as seen here for BTAF1 and RPL27 and RPL18 in mouse cells. We should note that 243 given the number of potential miR-132 targets involved in transcription (Fig. EV3C)[33], 244 we cannot exclude the contribution of additional miR-132 targets towards RP gene 245 regulation. Importantly, it is thought that the majority of RP genes are not regulated at 246 the post-transcriptional level by miRNAs due their relatively short 3'UTRs [34]. However, our work demonstrates that a miRNA can indirectly suppress a cluster of RP genes in 247 248 CD4⁺ T cells and MEFs. This reveals a novel mechanism of RP regulation with miR-132

acting as a molecular node mediating crosstalk between RP expression and post-transcriptional gene silencing.

251

The miR-212/132 cluster controls the balance between IL-10 and IFNγ production in CD4⁺ T cells.

254 Having shown that miR-132 deficiency results in similar transcriptomic effects in CD4⁺ 255 cells in vitro and in vivo (e.g. RP gene regulation, BTAF1 suppression) and during L. 256 donovani infection (Figs. 1 and 2), we measured capacity for IFNy and IL-10 production 257 by CD4⁺ T cells from infected mice by intracellular cytokine staining following ex vivo stimulation with PMA and ionomycin. We found a modest but significant reduction in the 258 ability of *miR-132^{-/-}* CD4⁺ T cells to produce IFN_Y (Fig. 4A). This was accompanied by 259 a greater fold increase in production of IL-10 by *miR-132^{-/-}* IFNy⁺ CD4⁺ T cells compared 260 to wild-type cells (Fig. 4B and Fig. EV4A). Interestingly, IL-10 mRNA levels were not 261 statistically significantly different between WT and miR-132^{-/-} cells (Fig. 4C), indicating 262 263 that miR-132 affected IL-10 expression at the post-transcriptional/translational level. Increased IL-10 production by miR-132^{-/-} CD4⁺ T cells was also evident following *in vitro* 264 265 restimulation of splenic CD4⁺ T cells from infected mice with L. donovani antigen 266 demonstrating that the effect was occurring in antigen-specific manner (Fig. EV4B). The 267 observed reduction in frequency of IFNy⁺ CD4⁺ T cells and an increase in frequency of 268 IFNy⁺IL-10⁺ CD4⁺ T cells is consistent with the concept that IL-10⁺ Th1 cells develop 269 after prolonged exposure to antigen and represent an endpoint of the Th1 response [35]. In this respect, our results can be interpreted as *miR-132^{-/-}* CD4⁺ T cells reaching this 270 271 endpoint immunoregulatory status prematurely.

At the molecular level, the increase in IFN γ^{+} IL-10⁺ CD4⁺ T cells *in vivo* was associated with a transcriptomic signature characterised by an up-regulation of a cluster of RP genes in *miR-132^{-/-}* CD4⁺ T cells (**Fig. 1D-E**). To further explore this finding we compared *in vitro* Th1 differentiation of WT and *miR-132^{-/-}* CD4⁺ T cells in presence or absence of phenylephrine (PE), which has been shown to enhance ribosome biosynthesis [36].

277 Remarkably, although there were no statistically significant differences between miR-132^{-/-} and WT cells, nor between WT DMSO-treated and PE-treated cells, treating miR-278 132^{-/-} CD4⁺ T cells with PE resulted in statistically significantly enhanced IL-10 279 expression and increased number of cells compared to WT cells. An increase in IL-10 280 281 levels was observed in PE-treated WT cells compared to DMSO-treated WT cells but 282 this did not reach statistical significance. IFN_y levels were not affected by PE and were lower in *miR-132^{-/-}* Th1 cells although this did not reach significance after multiple testing 283 284 correction (Fig. 4D-F). In agreement with our in vivo observations, the enhanced cell number and IL-10 expression under these in vitro conditions recapitulated enhanced 285 activation and premature acquisition of an immunoregulatory state in miR132^{-/-} CD4⁺ T 286 287 cells. Overall, these results demonstrated that miR-132 connects RP expression, IL-10 expression, and CD4⁺ T cell activation in Th1 cells. Our results infer that the observed 288 deregulation of selected RPs in miR-132^{-/-} CD4⁺ T cells in vivo likely alters the 289 290 composition and function of ribosomes in a manner that specifically promotes IL-10 291 expression. This could be potentially explained by formation of specialised ribosomes in 292 activated CD4⁺ T cells [37, 38].

293

294 The miR-212/132 cluster promotes protective immunity to *L. donovani*.

295 Having observed that loss of miR-132 favours an immunoregulatory (higher IL-10 expression) phenotype in Th1 cells, we tested the response of miR-132^{-/-} mice to L. 296 donovani infection. Indeed, IFNy⁺IL-10⁺ CD4⁺ T cells have been associated with immune 297 298 dysregulation and infection susceptibility in a variety of human and experimental 299 systems [39-43]. Furthermore, the role of IL-10 in preventing L. donovani clearance had 300 been previously demonstrated [44-46]. However this support comes from the study of 301 fully IL-10-deficient mice and use of blocking antibodies against IL-10 or its receptor. To 302 determine whether modest changes in IL-10 levels could alter infection outcomes, we infected *IL-10^{+/+}*, *IL-10^{+/-}* and *IL-10^{-/-}* mice. Infected *IL-10^{+/-}* mice produced intermediate 303 levels of IL-10 compared to their $IL-10^{+/+}$ and $IL-10^{-/-}$ counterparts (Fig. EV5A), without 304

305 any change in IFNy production (Fig. EV5B). Notably, as with WT mice treated with IL-10R-blocking antibody or *IL-10^{-/-}* mice, *IL-10^{+/-}* mice were able to clear liver parasites 306 307 albeit with slower kinetics (Fig. 5A). These experiments suggested that modifying the relative abundance of IL-10 and IFNy by reducing IL-10 by 50% can affect susceptibility 308 309 to L. donovani infection. Consistently with these findings and the observed IL-10 levels in miR-132^{-/-} mice, L. donovani infection resulted in significantly elevated splenic 310 parasite burdens in *miR-132^{-/-}* mice (**Fig. 5B**). Although we observed variation in parasite 311 load between different experiments (Fig. 5C), miR-132^{-/-} spleens consistently harboured 312 approximately 2-fold more parasites at day 28 compared to WT controls (Fig. 5C-D). In 313 addition to parasite loads miR-132 deficiency affected CD11b⁺ cell populations, here 314 called MoA (CD11b⁺ F4/80⁺ CD11c⁻), MoB (CD11b^{hi} F4/80^{hi} CD11c⁺), and MoC 315 (CD11b^{hi} F4/80^{lo} CD11c⁺) present in infected spleens (gated as Fig. EV5C). The 316 numbers of MoA and MoB cells decreased in infected *miR-132^{-/-}* mice characterised by 317 higher IL-10 expression in CD4⁺ T cells (Fig. EV5D). Conversely, numbers of these 318 populations increased in an IL-10 dose dependent manner, in infected $IL-10^{-/2}$ and to a 319 lesser extent in *IL-10^{+/-}* mice (Fig. EV5E), demonstrating that the number of these cells 320 321 is inversely correlated with IL-10 expression. Of note, IL-10 expression did not differ between WT and miR-132^{-/-} myeloid subpopulations (Fig. EV5F). This demonstrated 322 323 that the effect of miR-132 on IL-10 expression does not occur in all IL-10-producing cell 324 types, showing specificity for Th1 cells. Our findings do not exclude that miR-132-325 mediated suppression of IL-10 might occur in other cell types (e.g. B cells, innate 326 lymphoid cells) contributing to the overall function of miR-132 in immunity.

Liver parasite burdens peaked around day 21 and we noted increased levels in *miR*-328 *132^{-/-}* mice at this time point (**Fig. EV5G**). Whilst *miR-132^{-/-}* liver burdens were only 329 significantly elevated at day 28 when we corrected for inter-experiment variations in 330 infection intensity (**Fig. EV5H**), *miR-132^{-/-}* mice continued to harbour a significantly 331 elevated parasite burden at day 42 (**Fig. EV5I**), a time point when parasites are being 332 cleared from this organ in WT C57BL/6 mice [18]. Notably, the enhanced pathogen

burdens coincided with significantly smaller spleen and liver size in *miR-132^{-/-}* mice compared to their WT counterparts (**Fig. 5E-F**). The impact of miR-132 deficiency on hepatosplenomegaly was most pronounced at higher infection levels, with a similar trend also evident after infection with lower parasite doses (**Fig. EV5J-K**).

337 In sum, we propose that our findings support a model according to which enhanced ribosomal protein expression upon activation of miR-132^{-/-} CD4⁺ T cells in vivo 338 339 contributes towards accelerated activation of these cells and the premature switch to the IFNy⁺IL-10⁺ phenotype. Although we cannot exclude that other cell types or 340 mechanisms contribute to the observed increase in parasite loads in $miR-132^{-/-}$ mice, 341 we propose that the effects of miR-132 deficiency on IL-10 expression in IFN γ^+ CD4⁺ T 342 343 cells significantly contribute to reduced protective inflammation and enhanced susceptibility of *miR-132^{-/-}* mice to infection. This is consistent with previous publications 344 345 that highlight that IL-10 produced by Th1 cells (rather than regulatory T cells or myeloid 346 cells) is a critical determinant of L. donovani infection outcomes [40, 47]. Of note, due 347 to the impossibility of concurrent physiological knockdown or over-expression of RPs, the functional relevance of this family of proteins to Th1 responses in vivo has remained 348 elusive. Our results provide a novel conceptual framework for the in vivo relevance of 349 350 RP expression in CD4⁺ T cells indicating that exaggerated RP expression can be associated with impaired T cell responses. We propose that miR-132-driven 351 352 coordination of the machineries that control RNA metabolism is essential for optimal Th1 353 cell activation and protective immunity.

354

355 MATERIALS AND METHODS

356 Ethics

Animal care and experimental procedures were regulated under the Animals (Scientific Procedures) Act 1986 (revised under European Directive 2010/63/EU) and were performed under UK Home Office License (project licence number PPL 60/4377 with approval from the University of York Animal Welfare and Ethical Review Body). Animal

361 experiments conformed to ARRIVE guidelines.

362

363 Mice and L. donovani infection

Female C57BL/6 CD45.1, CD45.2, and RAG2^{-/-} mice were obtained from Charles River 364 (UK). *MiR-132/212^{-/-}* mice (complete knockouts) were provided by Dr Richard Goodman 365 (Vollum Institute, Oregon Health & Science University, USA). IL-10^{-/-} mice were provided 366 367 by Dr Anne O'Garra (Francis Crick Institute, UK) and were crossed with WT CD45.2 C57BL/6 mice to generate IL-10^{+/-} heterozygotes. All mice were bred in house, 368 maintained under specific pathogen-free conditions and used at 6 – 12 weeks of age. 369 The Ethiopian strain of *L. donovani* (LV9) was maintained by passage in RAG-2^{-/-} mice. 370 Mice were infected i.v. with 100x10⁶ amastigotes via the tail vein. Parasite doses of 10 371 and 30x10⁶ were also used where indicated. Parasite burden was expressed as 372 Leishman-Donovan units (LDU; the number of parasites per 1,000 host cell nuclei × 373 374 organ weight in mg)[48]. To allow comparison between these experiments, we 375 normalised LDU to the levels observed in WT mice (relative LDU). For IL-10R 376 neutralisation experiments mice were infected with L. donovani and received anti-IL10R 377 (Clone: 1B1.3A from Bio X Cell) or IgG isotype control (SIGMA) injections at day 0, 14, 378 and 21 p.i. at 0.5mg mAb/injection.

379

380 FACS analysis and cell sorting.

381 For FACS analysis, spleens were first digested with 0.4 U/ml Liberase TL (Roche) and 382 80 U/ml DNase I type IV in Hank's Balanced Salt Solution (both Sigma) for 15min at 383 37°C. Enzyme activity was inhibited with 10mM EDTA pH 7.5 and single cell 384 suspensions created with 70 µm nylon filters (BD Biosciences) in complete RPMI 1640 385 (ThermoFisher) supplemented with 10% heat inactivated FCS (HyClone), 100 U/ml 386 penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (all ThermoFisher). Red blood cells were lysed with red blood cell lysing buffer (Sigma), For live/dead discrimination, 387 388 cells were washed twice in PBS, then stained with Zombie Agua (Biolegend) before

389 resuspension in FACS buffer (PBS containing 0.5% BSA and 0.05% azide). Fc 390 receptors were blocked with 100µg/ml rat IgG (Sigma) for 10min at 4°C, before surface staining for 30min at 4°C. Combinations of the following anti-mouse antibodies were 391 392 used: CD45.1 APC (clone A20); CD45.2 BV786 (104); CD3 FITC (145-2C11); B220 393 FITC (RA3-6B2); TCRβ PE-Cy7 (H57-597); MHCII alexa700 (M5/114.15.2); Ly6G PE-Cy7 (1A8); CD11b PB and APC (M1/70); CD11c PerCP/Cy5.5 (N418); F4/80 FITC and 394 395 alexa647 (BM8); CD44 FITC (IM7); CD62L PE (MEL-14); CD8α APC (53-6.7); CD4 PE and PerCP/Cy5.5 (RM4-5); IFNy FITC (XMG1.2); IL-10 PE (JES5-16E3). All antibodies 396 were from Biolegend. To measure intracellular cytokines in T cells following ex vivo 397 stimulation, cells were first stimulated in complete RPMI for 4 hours at 37°C with 398 399 500ng/ml PMA, 1µg/ml ionomycin and 10µg/ml brefeldin A (all Sigma). For myeloid cells, 400 cells were cultured as above either in the absence of exogenous stimulation (brefeldin 401 A alone) or with E. coli O55:B5 LPS (1µg/ml with brefeldin A; Sigma). To measure antigen-specific cytokine production, CD4⁺ cells were purified by magnetic separation 402 403 (Miltenvi Biotech) from the spleens of day 28 L. donovani infected CD45.2 WT and miR-404 132^{-/-} mice and cultured for 3 days with naïve splenocytes (CD45.1 WT mice) as a source of antigen-presenting cells (0.5x10⁶ CD45.2⁺ Ld CD4⁺, 1x10⁶ CD45.1⁺ naïve 405 splenocytes). Cells were cultured either alone or with 1.5x10⁷ whole killed (freeze-406 407 thawed) L. donovani amastigotes as a source of parasite antigen. Brefeldin A was added 408 as above for the final 4 hours of culture to permit accumulation of intracellular cytokines. 409 CD45.2 and CD45.1 staining was used to assess cytokine production by CD4 T cells 410 from L. donovani-infected and naïve mice, respectively. For all intracellular cytokine 411 staining, surface stained cells were fixed and permeabilised (20min at 4°C) using 412 Fixation/Permeabilisation solution before washes in Perm/Wash buffer (both BD 413 Biosciences). Cells were then staining with intracellular antibodies as above except in 414 Perm/Wash buffer. Appropriate isotype controls were included. For FACS analysis, 415 events were acquired on a LSRFortessa (BD Biosciences) before analysis with FlowJo 416 (FlowJo LLC). For cell sorting of splenic lymphocytes from naïve and Ld-infected

417 spleens, B cells were gated as B220⁺ CD3⁻; CD4 T cells as B220⁻ CD3⁺ CD4⁺ CD8a⁻; and CD8 T cells as B220⁻ CD3⁺ CD4⁻ CD8a⁺. For purification of naïve and activated CD4 418 T cells from uninfected mice, single cell suspensions were prepared from pooled 419 420 spleens and peripheral LN (axillary, brachial and inguinal). CD4⁺ cells were enriched using CD4 microbeads and LS columns (both Miltenyi Biotec) before cell sorting of naïve 421 422 CD4 T cells (CD4⁺ CD62L⁺ CD44⁻ CD11b⁻ CD8a⁻ MHCII⁻). For cell sorting of splenic 423 myeloid cell populations, cells were gated as Fig. EV5C. Cell sorting was performed with 424 a MoFlo Astrios (Beckman Coulter) and sorted cells were typically >98% positive.

425

426 In vitro activation of CD4 T cells

427 Purified CD4 T cells were stimulated with 10µg/ml plate bound anti-CD3ε (clone 145-428 2C11) and 2µg/ml soluble anti-CD28 (37.51) in RPMI 1640 as before in flat bottom 96 well plates. For Th1 polarisation, cells were also treated with 15ng/ml recombinant 429 430 mouse IL-12 and 5µg/ml anti-IL-4 (11B11), or for Th2 polarisation, 30ng/ml recombinant 431 mouse IL-4 and 5µg/ml anti-IFNy (XMG1.2). Phenylephrine hydrochloride (Sigma) was 432 used at 10µM and added during both anti-CD3 dependent activation (4 days) and also 433 during rest in 10U/ml recombinant human IL-2 (2 days). All antibodies were from 434 Biolegend and were low endotoxin / azide free, and recombinant cytokines were from 435 Peprotech.

436

437 MEF cell culture, siRNA and miRNA mimic treatment

438 C57BL/6 MEFs were provided by Dr. D. Coverley (University of York, UK) and were 439 cultured in DMEM (high glucose and pyruvate; ThermoFisher) supplemented with 10% 440 FCS, pen-strep and L-glut as RPMI. For transfections, 5x10⁴ cells per well were seeded 441 in 6 well plates and transfected the next day with ON-TARGETplus SMARTpool siRNA 442 (100nM), miRIDIAN miRNA mimics (50nM), or appropriate controls (all Dharmacon, GE 443 Healthcare) using TransIT-siQUEST transfection reagent (Mirus) and Opti-MEM 444 medium (ThermoFisher) for 6 hours before being replaced with complete DMEM. EL4

445 cells were grown in RPMI supplemented with 10% FCS and were transfected with 446 miRNA mimics using Neon Nucleofection as per manufacturer's instructions. Non-447 targeting control (NTC) siRNAs or mimics were used as controls. Cells were harvested 448 hours after transfection.

449

450 Quantitative reverse transcription PCR (qRTPCR)

451 RNA was extracted from tissue samples or purified cell populations using QIAzol and 452 miRNeasy RNA extraction kits (QIAGEN) according to manufacturer's instructions. 453 Tissue samples were first dissociated in QIAzol using a Tissuelyser LT with stainless 454 steel beads (all QIAGEN, UK). For detection of mature miRNA, cDNA was synthesised 455 using Taqman miRNA reverse transcription kits, and levels determined with Taqman 456 miRNA assays and Tagman Universal PCR Master Mix (all ThermoFisher). For mRNA 457 transcripts, reverse transcriptions were carried out with Superscript III (ThermoFisher) 458 and random hexamer primers (Promega), and measured with Fast SYBR Green Master 459 Mix (ThermoFisher). PCR were performed using a StepOnePlus Real Time PCR 460 System (ThermoFisher) and relative transcript levels determined using the $\Delta\Delta$ Ct method. 461 Mature miRNA levels were normalised to U6. RNA transcript levels in T cells from L. 462 donovani-infected mice and MEFs were normalised to HPRT. As in vitro CD4 T cell 463 activation changes HPRT, GAPDH and β-actin expression levels, U6 was also used to 464 normalise mRNA expression in day 0 and 1 naïve T cells. The following primer 465 sequences were used:

- 466 BTAF1: Forward: 5'GCCTTTGGAAAGCTTTTGTG3', Reverse:
- 467 5'CCAGTACCTGCCCCATGT3'. HPRT: Forward:
- 468 5'GCGTCGTGATTAGCGATGATGAAC3', Reverse:
- 469 5'ATCTCCTTCATGACATCTCGAGCAAGTC3'. POLR2F: Forward:
- 470 5'GAGGAGGACGAAGGACTTGA3', Reverse: 5'CCAGATGGGAGAATCTCGAC3'.
- 471 RPL12: Forward: 5'CGAAGATCGGTCCTCTGG3', Reverse:
- 472 5'AATTCTGAGACCCTTCCAGTCA3'. RPL18: Forward:

- 473 5'CGCATGATCCGAAAGATGA3', Reverse: 5'AACTTCCAGAATCCGCACAT3'.
- 474 RPL26: Forward: 5'AGAAGGCTAATGGCACAACC3', Reverse:
- 475 5'TCCAGCTTTAGCCTGGTGAT3'. RPL27: Forward:
- 476 5'TGAAAGGTTAGCGGAAGTGC3', Reverse: 5'CATGAACTTGCCCATCTCG3'.
- 477 RPL8: Forward: 5'CAACAGAGCCGTTGTTGGT3', Reverse:
- 478 5'CAGCCTTTAAGATAGGCTTGTCA3'. RPS10: Forward:
- 479 5'GTGAGCGACCTGCAAGATTC3', Reverse: 5'CAGCCTCAGCTTTCTTGTCA3'.
- 480 RPS14: Forward: 5'AGTCTGGAGACGACGATCAGA3', Reverse:
- 481 5'CAGACACCAAACACATTCTCTCC3'. RPS30: Forward:
- 482 5'GGTCGCCCAGATCAAAGAT3', Reverse: 5'TGCCAGAAGCACGACTTG3'. RPS3A:
- 483 Forward: 5'TGGCAAGAAGGGAGCTAAGA3', Reverse:
- 484 5'GTGTCTTCCCGATGTTCCTAAT3'. RPS9: Forward:
- 485 5'ATCCGCCAACGTCACATTA3', Reverse: 5'TCTTCACTCGGCCTGGAC3'. RPSA:
- 486 Forward: 5'GGTCCATACGGCGTTGTT3', Reverse:
- 487 5'GCAGCAAGGAATTTGAGGAC3'. RPL14-ps1: Forward:
- 488 5'TGCTGCTGCTGCTAAAGCTA3', Reverse: 5'CAGCCTTCTTGCCTGGTC3'. RPL23-
- 489 ps3: Forward: 5'ATAAGGCCCGACGGAGAG3', Reverse:
- 490 5'GAATTAGCCATCTGGACTCAGTTT3'.
- 491

492 SDS-PAGE, Western blotting, and protein synthesis assays

493 Cells were washed twice in PBS and protein extracts prepared in RIPA buffer (150mM 494 NaCl, 10mM Tris pH 7.2, 5mM EDTA, 0.1% SDS, 0.1% Triton X-100, 1% sodium 495 deoxycholate, 1mM PMSF, 1% Protease Inhibitor cocktail P8340, 1% Phosphate 496 Inhibitors cocktails 2 and 3; all Sigma). Equal total amounts of protein were resolved on 497 SDS-PAGE gels and transferred to PVDF membranes (Millipore) using a BioRad SD 498 Semidry Transfer Cell, blocked for 2 hours at room temperature in 2% BSA 499 (ThermoFisher) or 5% milk powder (Sigma) in TBST (150mM NaCl, 7.7mM Tris HCl pH 500 8, 0.1% Tween 20; all Sigma) before overnight probing with primary antibodies at 4°C. 501 Antibodies were as follows: total CREB (clone 48H2), p-CREB S133 (87G3), BTAF1 502 (rabbit pAb #2637; all Cell Signaling Technology), p300 (clone NM11), Rpl27 (14980-1-503 AP, Proteintech), Rps9 (14894-1- AP, Proteintech), β-actin (AC-15), GAPDH (9484; all 504 Abcam). Following extensive washing in TBST, blots were incubated with secondary 505 antibodies (goat anti-rabbit or mouse HRP; DAKO) for 1 hour at room temp, washed as 506 before, and developed with ECL Western Blotting Detection Reagent and Hyperfilm ECL 507 (both GE Healthcare). Densitometry was performed using Fiji / ImageJ.

508 Protein synthesis rates were measured by puromycin incorporation [31]. Cells were 509 pulsed for 10 mins with 10μg/ml puromycin (Sigma) and then washed and incubated for 510 an extra 50 mins before lysed and used for western blotting analysis. Puromycin was 511 detected with the monoclonal antibody clone 12D10 (Merck Millipore).

512

513 **RNA sequencing analysis**

514 Sequence reads were trimmed to remove adaptor sequences with Cutadapt and 515 mapped to mouse genome GRCm38 with HISAT2[49] including "rna-strandness FR" option. Data available at GEO, accession number GSE125268. Transcriptome 516 517 assembly and quantification was performed using the Tuxedo pipeline (version 518 2.2.1)[50]. Cufflinks was used to assemble transcriptomes for each sample using the GTF annotation file for the GRCm38 mouse genome. This was followed by running 519 Cuffmerge to merge individual sample transcriptomes into full transcriptomes. 520 521 Quantification and normalisation were carried out for each experiment using Cuffguant 522 and Cuffnorm. Differential expression on gene FPKM values was performed by 523 conducting paired and independent t-tests with Benjamini-Hochberg false discovery rate 524 correction. GSEA (http://software.broadinstitute.org/gsea) and STRING analysis (http://string-db.org/) were performed where indicated. For analysis of genes 525 differentially expressed between WT and miR-132--- CD4 T cells from Ld-infected 526 527 spleens, transcripts were required to be significantly dysregulated (>50% change from 528 WT levels, p<0.05) with FPKM values>1, and STRING settings were highest confidence

interactions only excluding text mining. Targetscan (http://www.targetscan.org/vert_71/)
was used to predict targets of miRNA from the miR-212/132 cluster (cumulative
weighted context score++ <-0.1).

532

533 Luciferase assays

BTAF1 3'UTR was amplified from mouse spleen cDNA (reverse transcribed with 534 535 Superscript II and oligo-dT primers; both ThermoFisher) using the following primers : forward 5'CTCGAGTGCAACTGCTGCTAGCTCAGTTA3' (which introduces 5' Xho I 536 537 site) and reverse 5'GCGGCCGCTTATGAAAGCAGACAAGTA3' (which introduces 3' Not I site). The 1.5 kb amplicon, which encompasses most of the 3' UTR of BTAF1 538 minus a 25nt 5' GC rich stretch, was cloned into pGEM-T vector (Promega) and 539 540 sequence verified. We also performed site directed mutagenesis to remove the miR-541 212/132 seed sequence using QuikChange Site-Directed Mutagenesis (Agilent) with the 542 following primer pairs :

543 5'CTGAACCCTGTGGTAAAGACT**AAA**TACTGTAGCAGGGCCTGAAGC3' and 544 5'GCTTCAGGCCCTGCTACAGTA**TTT**AGTCTTTACCACAGGGTTCAG3', resulting in 545 mutation of WT sequence (5'AACCCUGUGGUAAA<u>GACU**GUU**</u>U3') to mutant 546 (5'AACCCUGUGGUAAA<u>GACU**AAA**</u>U3'). Inserts were excised with XhoI and NotI 547 (NEB) and ligated into psiCHECK-2 (Promega). Luciferase assays were performed in 548 HeLa and 3T3 cells 24 hours after transfection as previously described[3].

549

550 Statistical analysis

551 Statistical analyses were carried out as indicated with Prism 5 (Graphpad Software Inc). 552 Two-way comparisons used paired or unpaired t-tests as indicated and multiple 553 comparisons used one-way ANOVA, followed by Bonferroni correction for multiple 554 testing. P values of <0.05 were considered significant. * p<0.05, ** p<0.01, *** p<0.001, 555 **** p<0.0001. Statistical significance in enrichment of RP genes (as in Fig. 2I) were 556 determined using Chi-Square test.

557

558 ACKNOWLEDGEMENTS

The study was funded by the UK Medical Research Council through a New Investigator Research Grant (MR/L008505/1) awarded to D.L., a Programme Grant awarded to P.M.K. (G1000230), and a project Grant awarded to T.V.S. (MR/N009185/1). We would like to thank Dr R. Goodman and Dr G. Zhang for providing the *miR-132/miR-212* knockout mice, Dr A. O'Garra for the *IL-10* knockout mice, and Dr M. Kullberg for helpful discussions. We thank staff at the Imaging and Cytometry Lab in the University of York Bioscience Technology Facility for cell sorting and imaging support and advice.

566

567 AUTHORS CONTRIBUTIONS

568 D.L. conceived, designed, and supervised the project. D.L. and J.P.H. designed 569 experiments. P.M.K. and T.V.S. contributed to experimental design. J.P.H., K.M.S., N.B., 570 P.G., S.A.H. and D.L. performed experiments. J.P.H., K.N., K.M.S., and D.L. analysed 571 experiments. J.P.H. and D.L. wrote the manuscript. All authors critiqued and edited the

572 manuscript.

573

574 CONFLICT OF INTERESTS

575 The authors declare no conflict of interest.

576

577 **REFERENCES**

- 1. Mehta A, Baltimore D (2016) MicroRNAs as regulatory elements in immune
- 579 system logic. Nat Rev Immunol 16: 279-94
- 580 2. Wanet A, Tacheny A, Arnould T, Renard P (2012) miR-212/132 expression
- and functions: within and beyond the neuronal compartment. *Nucleic Acids Res*
- 582 **40**: 4742-53

Lagos D, Pollara G, Henderson S, Gratrix F, Fabani M, Milne RS, Gotch F,
 Boshoff C (2010) miR-132 regulates antiviral innate immunity through
 suppression of the p300 transcriptional co-activator. *Nat Cell Biol* **12**: 513-9

Nahid MA, Yao B, Dominguez-Gutierrez PR, Kesavalu L, Satoh M, Chan
 EK (2013) Regulation of TLR2-mediated tolerance and cross-tolerance through
 IRAK4 modulation by miR-132 and miR-212. *J Immunol* **190**: 1250-63

589 5. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq
590 H (2009) MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by
591 targeting acetylcholinesterase. *Immunity* **31**: 965-73

592 6. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-593 dependent induction of microRNA miR-146, an inhibitor targeted to signaling 594 proteins of innate immune responses. *Proc Natl Acad Sci U S A* **103**: 12481-6

595 7. Mehta A, Mann M, Zhao JL, Marinov GK, Majumdar D, Garcia-Flores Y, Du

596 X, Erikci E, Chowdhury K, Baltimore D (2015) The microRNA-212/132 cluster

regulates B cell development by targeting Sox4. J Exp Med 212: 1679-92

598 8. Mehta A, Zhao JL, Sinha N, Marinov GK, Mann M, Kowalczyk MS, Galimidi

599 RP, Du X, Erikci E, Regev A, et al. (2015) The MicroRNA-132 and MicroRNA-

600 212 Cluster Regulates Hematopoietic Stem Cell Maintenance and Survival with

601 Age by Buffering FOXO3 Expression. *Immunity* **42**: 1021-32

9. Hanieh H, Alzahrani A (2013) MicroRNA-132 suppresses autoimmune
encephalomyelitis by inducing cholinergic anti-inflammation: a new Ahr-based
exploration. *Eur J Immunol* 43: 2771-82

10. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K (2010) STAT3
activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the
epigenetic switch linking inflammation to cancer. *Mol Cell* **39**: 493-506

Li D, Wang A, Liu X, Meisgen F, Grunler J, Botusan IR, Narayanan S, Erikci
E, Li X, Blomqvist L, *et al.* (2015) MicroRNA-132 enhances transition from
inflammation to proliferation during wound healing. *J Clin Invest* **125**: 3008-26
Xiao J, Li Y, Prandovszky E, Karuppagounder SS, Talbot CC, Jr., Dawson
VL, Dawson TM, Yolken RH (2014) MicroRNA-132 dysregulation in Toxoplasma
gondii infection has implications for dopamine signaling pathway. *Neuroscience* **268**: 128-38

615 13. Ni B, Rajaram MV, Lafuse WP, Landes MB, Schlesinger LS (2014)
616 Mycobacterium tuberculosis decreases human macrophage IFN-gamma
617 responsiveness through miR-132 and miR-26a. *J Immunol* **193**: 4537-47

Magill ST, Cambronne XA, Luikart BW, Lioy DT, Leighton BH, Westbrook
GL, Mandel G, Goodman RH (2010) microRNA-132 regulates dendritic growth
and arborization of newborn neurons in the adult hippocampus. *Proc Natl Acad Sci U S A* **107**: 20382-7

622 15. Asmal M, Colgan J, Naef F, Yu B, Lee Y, Magnasco M, Luban J (2003)

623 Production of ribosome components in effector CD4+ T cells is accelerated by

624 TCR stimulation and coordinated by ERK-MAPK. *Immunity* **19**: 535-48

625 16. Vo N, Klein ME, Varlamova O, Keller DM, Yamamoto T, Goodman RH,

626 Impey S (2005) A cAMP-response element binding protein-induced microRNA

627 regulates neuronal morphogenesis. Proc Natl Acad Sci U S A 102: 16426-31

17. Kaiser M, Wiggin GR, Lightfoot K, Arthur JS, Macdonald A (2007) MSK
regulate TCR-induced CREB phosphorylation but not immediate early gene
transcription. *Eur J Immunol* **37**: 2583-95

631 18. Kaye P, Scott P (2011) Leishmaniasis: complexity at the host-pathogen
632 interface. *Nat Rev Microbiol* **9**: 604-15

19. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van
Dongen S, Grocock RJ, Das PP, Miska EA, *et al.* (2007) Requirement of
bic/microRNA-155 for normal immune function. *Science* **316**: 608-11

- 636 20. Yang L, Boldin MP, Yu Y, Liu CS, Ea CK, Ramakrishnan P, Taganov KD,
- 637 Zhao JL, Baltimore D (2012) miR-146a controls the resolution of T cell responses
- 638 in mice. J Exp Med **209**: 1655-70
- 639 21. Grigoryev YA, Kurian SM, Hart T, Nakorchevsky AA, Chen C, Campbell D,
- 640 Head SR, Yates JR, 3rd, Salomon DR (2011) MicroRNA regulation of molecular
- 641 networks mapped by global microRNA, mRNA, and protein expression in 642 activated T lymphocytes. *J Immunol* **187**: 2233-43
- 643 22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette
 644 MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, *et al.* (2005) Gene set
 645 enrichment analysis: a knowledge-based approach for interpreting genome-wide
 646 expression profiles. *Proc Natl Acad Sci U S A* **102**: 15545-50
- 647 23. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-
- 648 Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. (2015) STRING v10:
- 649 protein-protein interaction networks, integrated over the tree of life. *Nucleic Acids*
- 650 *Res* **43**: D447-52
- 651 24. Stubbington MJ, Mahata B, Svensson V, Deonarine A, Nissen JK, Betz AG,
- Teichmann SA (2015) An atlas of mouse CD4(+) T cell transcriptomes. *Biol Direct* 10: 14
- Tan TCJ, Knight J, Sbarrato T, Dudek K, Willis AE, Zamoyska R (2017)
 Suboptimal T-cell receptor signaling compromises protein translation, ribosome
 biogenesis, and proliferation of mouse CD8 T cells. *Proc Natl Acad Sci U S A* **114**: E6117-E6126

658 26. Nosrati N, Kapoor NR, Kumar V (2014) Combinatorial action of transcription
659 factors orchestrates cell cycle-dependent expression of the ribosomal protein
660 genes and ribosome biogenesis. *FEBS J* 281: 2339-52

661 27. Perry RP (2005) The architecture of mammalian ribosomal protein
662 promoters. *BMC Evol Biol* **5**: 15

663 28. Thomas MJ, Seto E (1999) Unlocking the mechanisms of transcription 664 factor YY1: are chromatin modifying enzymes the key? *Gene* **236**: 197-208

665 29. Auble DT, Wang D, Post KW, Hahn S (1997) Molecular analysis of the 666 SNF2/SWI2 protein family member MOT1, an ATP-driven enzyme that

667 dissociates TATA-binding protein from DNA. Mol Cell Biol 17: 4842-51

668 30. Choukrallah MA, Kobi D, Martianov I, Pijnappel WW, Mischerikow N, Ye T,

669 Heck AJ, Timmers HT, Davidson I (2012) Interconversion between active and

670 inactive TATA-binding protein transcription complexes in the mouse genome.

671 Nucleic Acids Res **40**: 1446-59

672 31. Schmidt EK, Clavarino G, Ceppi M, Pierre P (2009) SUnSET, a

673 nonradioactive method to monitor protein synthesis. Nat Methods 6: 275-7

674 32. Venters BJ, Irvin JD, Gramlich P, Pugh BF (2011) Genome-wide
675 transcriptional dependence on conserved regions of Mot1. *Mol Cell Biol* **31**:
676 2253-61

Alvarez-Saavedra M, Antoun G, Yanagiya A, Oliva-Hernandez R, CornejoPalma D, Perez-Iratxeta C, Sonenberg N, Cheng HY (2011) miRNA-132
orchestrates chromatin remodeling and translational control of the circadian
clock. *Hum Mol Genet* **20**: 731-51

34. Ledda M, Di Croce M, Bedini B, Wannenes F, Corvaro M, Boyl PP,
Caldarola S, Loreni F, Amaldi F (2005) Effect of 3'UTR length on the translational
regulation of 5'-terminal oligopyrimidine mRNAs. *Gene* **344**: 213-20

35. Cope A, Le Friec G, Cardone J, Kemper C (2011) The Th1 life cycle:
molecular control of IFN-gamma to IL-10 switching. *Trends Immunol* 32: 278-86
36. Zhang Z, Liu R, Townsend PA, Proud CG (2013) p90(RSK)s mediate the
activation of ribosomal RNA synthesis by the hypertrophic agonist phenylephrine
in adult cardiomyocytes. *J Mol Cell Cardiol* 59: 139-47

37. Segev N, Gerst JE (2018) Specialized ribosomes and specific ribosomal
protein paralogs control translation of mitochondrial proteins. *J Cell Biol* 217:
117-126

692 38. Xue S, Barna M (2012) Specialized ribosomes: a new frontier in gene
693 regulation and organismal biology. *Nat Rev Mol Cell Biol* **13**: 355-69

694 39. Anderson CF, Oukka M, Kuchroo VJ, Sacks D (2007)
695 CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune
696 suppression in chronic cutaneous leishmaniasis. *J Exp Med* 204: 285-97

40. Jankovic D, Kullberg MC, Feng CG, Goldszmid RS, Collazo CM, Wilson M,

698 Wynn TA, Kamanaka M, Flavell RA, Sher A (2007) Conventional T-

699 bet(+)Foxp3(-) Th1 cells are the major source of host-protective regulatory IL-10

700 during intracellular protozoan infection. J Exp Med 204: 273-83

701 41. Nylen S, Maurya R, Eidsmo L, Manandhar KD, Sundar S, Sacks D (2007)

702 Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3)

regulatory T cells in human visceral leishmaniasis. J Exp Med 204: 805-17

42. Owens BM, Beattie L, Moore JW, Brown N, Mann JL, Dalton JE, Maroof A,

705 Kaye PM (2012) IL-10-producing Th1 cells and disease progression are

706 regulated by distinct CD11c(+) cell populations during visceral leishmaniasis.
707 *PLoS Pathog* 8: e1002827

43. Saraiva M, Christensen JR, Veldhoen M, Murphy TL, Murphy KM, O'Garra
A (2009) Interleukin-10 production by Th1 cells requires interleukin-12-induced
STAT4 transcription factor and ERK MAP kinase activation by high antigen dose. *Immunity* **31**: 209-19

Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, Rai M, Sundar S, Sacks
D (2011) IL-10 neutralization promotes parasite clearance in splenic aspirate
cells from patients with visceral leishmaniasis. *J Infect Dis* 204: 1134-7
Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP (2001) IL-10

716 mediates susceptibility to Leishmania donovani infection. *Eur J Immunol* **31**:717 2848-56

46. Murray HW, Moreira AL, Lu CM, DeVecchio JL, Matsuhashi M, Ma X,
Heinzel FP (2003) Determinants of response to interleukin-10 receptor blockade
immunotherapy in experimental visceral leishmaniasis. *J Infect Dis* 188: 458-64
47. Ranatunga D, Hedrich CM, Wang F, McVicar DW, Nowak N, Joshi T,
Feigenbaum L, Grant LR, Stager S, Bream JH (2009) A human IL10 BAC
transgene reveals tissue-specific control of IL-10 expression and alters disease
outcome. *Proc Natl Acad Sci U S A* 106: 17123-8

48. Dalton JE, Maroof A, Owens BM, Narang P, Johnson K, Brown N,
Rosenquist L, Beattie L, Coles M, Kaye PM (2010) Inhibition of receptor tyrosine
kinases restores immunocompetence and improves immune-dependent
chemotherapy against experimental leishmaniasis in mice. *J Clin Invest* 120:
1204-16

- 730 49. Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced aligner with
- 731 low memory requirements. Nat Methods 12: 357-60

50. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H,
Salzberg SL, Rinn JL, Pachter L (2012) Differential gene and transcript
expression analysis of RNA-seq experiments with TopHat and Cufflinks. *Nat Protoc* 7: 562-78

736

737 FIGURE LEGENDS

Figure 1: The miR-132/212 cluster regulates RP mRNA levels in CD4⁺ T cells from
chronically infected spleens.

A. Expression of indicated miRNAs in sorted naïve (CD62L⁺ CD44⁻) CD4⁺ T cells and following *in vitro* stimulation with anti-CD3 / anti-CD28 (1-3 days), relative to levels in cells prior to stimulation. Data from 3 independent experiments each using T cells pooled from 4 WT mice. Significance determined by one-way ANOVA.

B. Expression of indicated miRNAs in purified spleen lymphocytes (B cells, CD4⁺ T cells
and CD8⁺ T cells) from d0 naive (white) and day 28 *L. donovani*-infected (grey) mice.
Expression of each miRNA normalized to levels in whole naïve spleen (dotted line). Data
is mean + SEM of 2 experiments with cells purified from 3-5 pooled spleens.

C. Volcano plot of RNAseq gene expression in splenic WT and *miR-132^{-/-}* CD4⁺ T cells from d28 *L. donovani* infected mice. Fold change determined as log2 mean FPKM (*miR-132^{-/-}*/WT) from 4 WT and 5 *miR-132^{-/-}* mice. Transcripts significantly different between WT and miR-132^{-/-} (p<0.05) are shown in red. Dotted box indicates transcripts significantly up-regulated in miR-132^{-/-} CD4⁺ T cells by more than 50%.

D. STRING network analysis of significantly up-regulated transcripts in CD4⁺ T cells from spleen of d28 *L. donovani* infected *miR-132^{-/-}* mice compared to WT cells. Cluster of ribosomal proteins shown in green circle, with coding RP transcripts (black) and pseudogenes (red) indicated. Secondary clusters are shown in grey.

E. Top enriched molecular function Gene Ontology terms for genes significantly upregulated in CD4⁺ T cells from spleens of infected *miR-132^{-/-}* mice compared to WT mice. **F.** Volcano plot of all RP genes in splenic WT and *miR-132^{-/-}* CD4⁺ T cells from d28 *L*. *donovani* infected mice. RPL genes are shown as circles, RPS genes as triangles, and
pseudogenes as squares. Red symbols indicate significant difference between WT and
miR-132^{-/-} cells (p<0.05) whereas black non-significant.

G. Expression of RP transcripts determined by qPCR from *L. donovani* infected d28 WT (blue) and *miR-132^{-/-}* mice (red). N=9 for each WT and *miR-132^{-/-}* from 2 independent infection experiments. Box extends from 25-75th percentile, whiskers are minimum and maximum values, and horizontal lines indicate median. Significance determined by unpaired t-test.

H. Fold change of all RP transcripts (grey) in Th1 cells compared to naïve CD4⁺ T cells.
Data taken from RNA sequencing experiments described in reference 24. Fold changes
in IL-10 (red) and IFNγ (blue) indicated for comparison. The statistical significance of
the observed up-regulation of RP transcripts in Th1 cells is determined by Chi-squared
test.

773 **Data information:** * p<0.05, ** p<0.01, *** p<0.001.

774

775 Figure 2: The B-TFIID cofactor BTAF1 is a direct miR-132 target in CD4⁺ T cells.

A. Volcano plot ($Log_{2}(Fold Change)$ vs -Log(P value)) of RNA gene expression in purified naïve CD62L⁺ CD44⁻ WT and *miR-132^{-/-}* CD4⁺ T cells. Fold change determined as log2 mean FPKM (*miR-132^{-/-}*/WT) from 4 WT and 4 *miR-132^{-/-}* mice. Transcripts significantly different between WT and *miR-132^{-/-}* cells (p<0.05) shown in red.

B. Volcano plot of RNA gene expression in purified naïve CD62L⁺ CD44⁻ WT and *miR*-132^{-/-} CD4⁺ T cells following 18hr *in vitro* stimulation with anti-CD3/anti-CD28 under Th1 conditions. Fold change determined as log2 mean FPKM (*miR-132*^{-/-}/WT) from 4 WT and 4 *miR-132*^{-/-} mice. Transcripts significantly different between WT and *miR-132*^{-/-} cells (p<0.05) shown in red.

785 **C.** Volcano plot of transcripts containing a conserved miR-212/132-3p target site in 786 naïve CD4⁺ T cells from WT or *miR-132^{-/-}* mice.

787 D. Volcano plot of transcripts containing a conserved miR-212/132-3p target site in *in vitro* polarised (Th1 condtions, 18h post stimulation) CD4⁺ T cells from WT or *miR-132⁻* 789 ^{-/-} mice.

F. Volcano plot of transcripts containing a conserved miR-212/132-3p target site in
spleen CD4⁺ T cells from d28 *L. donovani* infected WT or *miR-132^{-/-}* mice.

792 **F.** BTAF1 transcript levels determined by qRTPCR in WT (blue) or *miR-132^{-/-}* (red) in

naïve (d0) and Th1 polarised for 18h (d1) CD4⁺ T cells, and CD4⁺ T cells from d28 L.

794 donovani infected WT or miR-132^{-/-} mice. N=8-9 for each WT and miR-132^{-/-}.

795 G. Expression of BTAF1 protein in d0 naïve and d1 (18hr) Th1-polarised WT and miR-

796 132^{-/-} CD4⁺ T cells, as determined by Western blot. Each lane from individual mouse,

and representative of two independent experiments.

798 **H.** Relative luciferase activity in HeLa transfected with plasmid containing WT *BTAF1*

3'UTR (white) or BTAF1 3'UTR on which the miR-132 binding site is mutated (grey)

800 downstream of renilla luciferase, in the presence of miR-132-3p or miR-212-3p mimics.

801 Error bars indicate SEM from eight replicate treatments.

B02 Data information: Significance in (F) and (H) determined by unpaired t-test. * p<0.05, **
803 p<0.01.

804

805

806 Figure 3: miR-132 and its targets p300 and BTAF1 control RP expression.

807 A. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected

808 with Non-targeting control (NTC) mimics (white) or miR-132-3p mimics (grey).

809 B. p300 and BTAF1 protein levels in MEF transfected with NTC mimics or miR-132-3p

810 mimics determined by Western blot. GAPDH was used as a loading control. Right panel

811 indicates mean + SEM of 4 experiments.

812 C. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected

813 with NTC siRNA (white) or p300 siRNA (grey).

814 D. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected

815 with NTC siRNA (white) or BTAF1 siRNA (grey).

816 E. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected

817 with NTC or miR-132-3p mimics and NTC siRNA or p300 or BTAF1 siRNAs for 48h.

818 Levels are normalised to cells transfected with NTC siRNA and NTC mimic.

819 **F.** Puromycin incorporation (following 10-minute pulse and 50-minute chase) 820 determined by western blot in MEFs transfected with NTC or miR-132-3p or miR-212-

821 3p mimics.

B22 Data information: Statistical significance is determined by unpaired t-test from 4-6
B23 experiments. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

824

825

826 Figure 4: miR-132 controls the balance between IL-10 and IFNγ production in CD4⁺

827 **T cells.**

828 A. Percentage of IFN γ^+ live TCR β^+ CD4⁺ cells from *L. donovani* infected WT (blue) or

829 *miR-132^{-/-}* (red) mice, determined by intracellular cytokine staining. Data representative
830 of 3 independent experiments with 3-5 mice per group.

831 **B**. Percentage of IFN γ^+ /IL-10⁺ live TCR β^+ CD4⁺ cells from *L. donovani* infected WT (blue) 832 or *miR-132^{-/-}* (red) mice, determined by intracellular cytokine staining. Data 833 representative of 3 independent experiments with 3-5 mice per group.

834 **C.** IL-10 mRNA levels, determined by RNA-sequencing, in TCR β^+ CD4⁺ cells purified

from spleens of *L. donovani* infected WT (blue) or $miR-132^{-/-}$ (red) mice (n=5 per group).

836 **D.** Percentage of IFN γ^+ WT (blue) or *miR-132^{-/-}* (red) *in vitro* polarised Th1 cells (6 days)

837 in the presence or absence of phenylephrine (PE), determined by intracellular cytokine

838 staining.

E. Percentage of IL10⁺ WT (blue) or *miR-132^{-/-}* (red) *in vitro* polarised Th1 cells (6 days)
in the presence or absence of phenylephrine (PE), determined by intracellular cytokine
staining.

F. Total cell counts following *in vitro* Th1 polarisation (6 days) in the presence or absence of phenylephrine (PE). For (D-E), cells were purified from 3 mice per group and 6 replicates performed.

845

Data information: For (A and B) statistical significance was determined by unpaired ttest. For (D–F), significance was determined with 1-way ANOVA followed by Bonferroni's multiple comparison test. * p<0.05, ** p<0.01, *** p<0.001. NS: not significant.

- 850
- 851

852 Figure 5: miR-132 promotes protective immunity to *L. donovani*.

853 A. Liver LDU (Leishman Donovan units) at day 28 in infected WT mice treated with anti-

854 IL-10R antibody or isotype control antibody (left panel, n=5 mice per group), or at day

855 21 and day 28 from WT (blue), $IL-10^{+/-}$ (open green circles) and $IL-10^{-/-}$ (filled green

856 circles) mice (right panel n= 3-6 mice per group)

857 **B.** Day 28 splenic parasite burdens expressed as LDU with each data point representing

858 an individual mouse in WT (blue) and miR-132-/-; red) mice. Data from 4

859 independent infection experiments.

860 **C.** Mean WT and *miR-132^{-/-}* spleen parasite burdens from the 4 independent 861 experiments shown in **(B)**. Lines link individual experiments.

862 **D.** Splenic parasite burdens relative to WT group (WT mean = 1) for each of the 4

863 experiments shown in (**B**), with each data point representing individual mouse.

864 E. Spleen size expressed as % body weight for d0 (naïve) or day 28 L. donovani infected

865 WT (blue) and *miR-132^{-/-}* (miR-132-/-; red) mice.

866 F. Liver size expressed as % body weight for d0 (naïve) or day 28 L. donovani infected

867 WT (blue) and $miR-132^{-/-}$ (red) mice.

Data information: Significance determined by unpaired t-test, and in (C) by paired t-test
of mean values. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

870

871

872 EXPANDED VIEW FIGURE LEGENDS

873

874 Expanded View Figure EV1: The miR-132/212 cluster regulates RP mRNA levels
875 in CD4⁺ T cells from chronically infected spleens.

876 **A.** Expression of phosphorylated CREB (Ser133), total CREB and β -actin loading

control in naïve CD4⁺ T cells cultured for indicated number of hours in presence (+) or absence (-) of anti-CD3 / anti-CD28, as determined by Western blot. Numbers indicate intensity normalised to 1 hour unstimulated samples (lane 1) and corrected by β-actin loading control. Representative of two independent experiments from 3 pooled mice each.

882 **B.** Relative expression of miR-132-3p and miR-212-3p determined by qPCR in naïve

883 mouse CD4⁺ T cells stimulated with anti-CD3/anti-CD28 for 18 hours under Th0 (non-

884 polarising; white), Th1 (rlL-12/anti-IL-4; grey) or Th2 conditions (rlL-4/anti-IFNγ; black)

relative to level in naïve cells prior to stimulation.

C. Fold change of all RP transcripts (grey) in Th2 cells compared to naïve CD4 T cells.
Data taken from RNA sequencing experiments described in reference 24. Fold changes
in IL-10 (red) and IL-4 (blue) indicated for comparison. The statistical significance of the
observed up-regulation of RP transcripts in Th1 cells is determined by Chi-squared test.

891 Expanded View Figure EV2: The B-TFIID cofactor BTAF1 is a direct miR-132 target
892 in CD4⁺ T cells.

A. Volcano plot of RNAseq gene expression in purified CD62L⁺ CD44⁻ naïve WT cells
before and after 1 day (18h) stimulation with anti-CD3/anti-CD28. Fold change
determined as log2 mean FPKM (stimulated / pre-stimulation) from 4 WT mice.
Transcripts significantly different (p<0.05) shown in red.

B. Volcano plot of RNAseq gene expression in purified CD62L⁺ CD44⁻ naïve *miR-132^{-/-}*cells before and after 1 day (18h) stimulation with anti-CD3/anti-CD28. Fold change
determined as log2 mean FPKM (stimulated / pre-stimulation) from 4 WT mice.
Transcripts significantly different (p<0.05) shown in red.

90**C. C.** RNAseq gene expression levels of BTAF1 from pre-stimulation (d0), 18h anti-902 CD3/anti-CD28 (d1) and the spleen of d28 *L. donovani* infection (Ld), from WT (blue) 903 and $miR-132^{-/-}$ (red) mice (n=4-5 mice per group). Significance determined by unpaired 904 t-test as indicated.

905 D. Schematic of miR-212/132-3p 7mer-m8 site in the 3'UTR of *BTAF1* transcript,
906 showing conservation in human, mouse and chimp. The site is also conserved in, rhesus,
907 squirrel, rabbit, pig, cow, cat, dog, brown bat, elephant, opossum, macaw and chicken;
908 but not rat or lizard.

909 **E.** Relative luciferase activity in mouse 3T3 cells transfected with plasmid containing 910 WT (white) or miR-212/132-mutant (grey) *BTAF1* 3'UTR immediately downstream of 911 renilla luciferase, in the presence of miR-132-3p or miR-212-3p mimics. Error bars 912 indicate SEM from eight replicate treatments. Significance determined by unpaired t-913 test.

914 F. Nucleotide sequences of mouse mature miRNA derived from miR-212/132 cluster.915 Seed sequences indicated in bold.

G. Volcano plots of RNAseq gene expression for transcripts containing a poorly
conserved miR-132-5p site (upper panels) or a broadly evolutionary conserved miR212-5p site (lower panels). Fold change determined as log2 mean FPKM *miR-132^{-/-}*/WT) from 4 WT and *miR-132^{-/-}* mice. Transcripts significantly different between WT and
miR-132^{-/-} (p<0.05) shown in red. Data compares pre-stimulation naïve CD4 T cells (d0,

921 left panels); after 18h in vitro stimulation with anti-CD3/anti-CD28 (d1, middle panels);

922 and from the spleens of d28 *L. donovani*-infected mice. Transcripts that are significantly

923 different (p<0.05) and show >2 fold change in expression are indicated.

924 **H.** RNA levels of BACH2 (based on RNA-seq) from pre-stimulation (d0), 18h anti-925 CD3/anti-CD28 (d1) and the spleen of d28 *L. donovani* infection (Ld), from WT (blue) 926 and $miR-132^{-/-}$ (red) mice. Significance determined by unpaired t-test as indicated (n = 927 4-5 mice per group).

I. Log2 fold change (LFC) in RP genes after 18 hours *in vitro* stimulation of WT (blue)
or miR-132^{-/-} naïve CD4⁺ T cells with anti-CD3/anti-CD28. Percentages of up-regulated
and down-regulated transcirpts in WT (40%) and *miR-132^{-/-}* (61%) cells are shown.
Statistical significance is determined with Chi-squared test.

932 J) DeltaLFC (LFC^{miR-132-/-} - LFC^{WT}) after 18 hours in vitro stimulation of WT (blue) or miR-

933 132^{-/-} naïve CD4⁺ T cells with anti-CD3/anti-CD28. Significance is determined with Chi-

934 squared test. **Data information:** * p<0.05, ** p<0.01.

935

936

937 Expanded View Figure EV3: miR-132 and its targets p300 and BTAF1 control RP

938 expression.

939 A. mRNA levels of indicated RP transcripts determined by qRTPCR in MEFs transfected

940 with NTC mimics (white) or miR-212-3p mimics (grey). Cultures performed in triplicate.

941 Statistical significance determined by t-test.

942 **B.** Protein levels determined by western blot of RPL27 and RPS10 in MEFs transfected

943 with NTC, miR-132-3p, or miR-212-3p mimics for 48h.

944 C. Top enriched molecular function GO terms for miR-132/212-3p predicted target

945 genes. Predictions retrieved from Targetscan, total context score <-0.1.

946 **D.** Protein levels determined by western blot of BTAF1 and p300 in EL4 cells transfected

947 with NTC, miR-132-3p, or miR-212-3p mimics for 48h.

948 **Data information:** * p<0.05, ** p<0.01.

949

950 Expanded View Figure EV4: miR-132 controls the balance between IL-10 and IFNγ 951 production in CD4⁺ T cells.

952 **A.** Intracellular cytokine staining of WT or *miR-132^{-/-}* splenic live CD45.2⁺ TCR β^+ CD4⁺ 953 cells for IFN γ and IL-10 from d0 naïve and day 28 *L. donovani* infected mice following 954 *ex vivo* stimulation (4hrs) with PMA and ionomycin.

- **B.** Antigen-specific IFNy and IL-10 production by splenic CD4⁺ T cells from CD45.2⁺ L. 955 donovani-infected WT (blue) or miR-132^{-/-} (red) mice was assessed as described in 956 957 materials and methods. Cells were cultured for 3 days in the absence of exogenous 958 stimulation ("Neg", open circles) or with parasite antigen ("Ag", closed circles), after 959 which cytokine production by CD4⁺ T cells from infected ("CD45.2") or naïve mice 960 ("CD45.1") was determined. Representative FACS plots for antigen-stimulated CD45.2⁺ 961 cells are shown. Significance determined by unpaired t-test, purified CD4⁺ T cells from 962 4-5 mice per group.
- 963

964 Expanded View Figure 5: miR-132 promotes protective immunity to *L. donovani*.

965 **A.** Percentage of IL10⁺ splenic live CD45.2⁺ TCR β^+ CD4⁺ cells for IL-10 in d0 naïve and

966 d21 in *L. donovani*-infected WT (blue), *IL-10^{+/-}* (open green) and *IL-10^{-/-}* (filled green)

967 mice. d21 used due to accelerated parasite clearance and immune resolution in IL-10^{-/-}

968 mice. Significance determined by ANOVA compared to WT group (n=3-5 per group).

969 **B.** Percentage of IFN γ^+ splenic live CD45.2⁺ TCR β^+ CD4⁺ cells for IL-10 in d0 naïve and

970 d21 in *L. donovani*-infected WT (blue), *IL-10^{+/-}* (open green) and *IL-10^{-/-}* (filled green)

971 mice. d21 used due to accelerated parasite clearance and immune resolution in IL-10^{-/-}

972 mice. Significance determined by ANOVA compared to WT group.

973 **C.** Gating strategy for defining distinct myeloid populations in infected mice shown in C.

974 NBNT = non-B non-T i.e. B220⁻ CD3⁻ in d0 naïve and d28 infected WT mice.

975 **D.** Total spleen cell numbers or of indicated myeloid populations in d0 naïve and d28 976 *Ld*-infected WT (blue) or *miR-132^{-/-}* (red) mice. Myeloid cells gated as live CD45.2⁺ CD3⁻ 977 B220⁻ Ly6G⁻ SS^{Io} singlets then; DC (CD11c⁺ F4/80⁻ MHCII⁺); M ϕ A (CD11b⁺ F4/80⁺ 978 CD11c⁻); M ϕ B (CD11c⁺ F4/80⁺ CD11b^{Io}); and M ϕ C (CD11c⁺ F4/80⁺ CD11b^{hi}). Bars 979 show mean + SEM. Data pooled from two independent experiments (n=4-5 per group 980 for each experiment). Significance determined by unpaired t-test as indicated.

981 **E.** Total spleen cell numbers or of indicated myeloid populations in d0 naïve and d21 982 *Ld*-infected WT (blue), *IL-10^{+/-}* (open green) and *IL-10^{-/-}* (filled green) mice (n=3-5 per 983 group). Myeloid cells gated as in (**D**). Bars show SEM. Significance determined by one-984 way ANOVA and is shown compared to WT group.

F. Spontaneous and LPS-induced IL-10 production by indicated spleen myeloid
populations (as in D) from N (naive) and *Ld*-infected mice (d28), determined by
intracellular cytokine staining. n.d. not detected i.e. cell type absent in naïve mice.
Significance determined by unpaired t-test as indicated, and data pooled from 2
independent experiments each with 3-5 mice per group. Bars show mean + SEM
G. Day 21 liver parasite burdens expressed as LDU (Leishman Donovan units) in WT
(blue) and *miR-132^{-/-}* (red) mice. Each data point represents an individual mouse.

992 Significance determined by unpaired t-test

993 **H.** Left hand panel: Day 28 liver parasite burdens expressed as LDU (Leishman 994 Donovan units) in WT (blue) and $miR-132^{-/-}$ (red) mice. Right hand panel shows same 995 data expressed relative to WT levels (WT mean = 1). Data from 4 independent infection 996 experiments with 4-5 mice per group per experiment. Significance determined by 997 unpaired t-test.

998 I. Day 42 liver parasite burdens expressed as LDU (Leishman Donovan units) in WT
999 (blue) and *miR-132^{-/-}* (red) mice. Each data point represents an individual mouse.
1000 Significance determined by unpaired t-test.

1001J. J.Spleen size expressed as % body weight for naïve (= 0 parasite dose) or day100228 L. donovani infected WT (blue) and miR-132^{-/-} (red) mice. Mice were infected with 10,

1003 30 or 100x10⁶ *L. donovani* amastigotes. Data pooled from 2 independent experiments
1004 with 3-5 mice per group. Significance determined by unpaired t-test.

- 1006 K. Liver size expressed as % body weight for naïve (= 0 parasite dose) or day 28 L.
- 1007 donovani infected WT (blue) and miR-132^{-/-} (red) mice. Mice were infected with 10, 30
- 1008 or 100x10⁶ L. donovani amastigotes. Data pooled from 2 independent experiments with
- 1009 3-5 mice per group. Significance determined by unpaired t-test. Boxes for (J-K) extend
- 1010 from 25-75th percentile, whiskers are minimum and maximum values, and horizontal
- 1011 lines indicate median
- 1012 Data information: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.
- 1013




Fig. 2




Fig. 3






Fig. 4








Fig. 5









Β.

	miRNA mimic		
		miR	miR
	NTC	132	212
RPL27	-		
RPS10	-	-	4
β-actin	-	-	-

D.

Molecular Pathway	FDR q-value
GO NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY	3.83E-20
GO REGULATORY REGION NUCLEIC ACID BINDING	6.39E-16
GO SEQUENCE SPECIFIC DNA BINDING	2.55E-13
GO RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY	
SEQUENCE SPECIFIC DNA BINDING	4.55E-13
GO TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE	
PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING	2.99E-12
GO MACROMOLECULAR COMPLEX BINDING	4.98E-11
GO DOUBLE STRANDED DNA BINDING	1.41E-10
GO RNA BINDING	1.97E-10
GO CHROMATIN BINDING	1.97E-10
GO CORE PROMOTER PROXIMAL REGION DNA BINDING	1.69E-09

miRNA mimic NTC miR-132 miR-212 p300 BTAF1 β-actin

